Literature DB >> 34852411

Agreement Between the TEG 6s and TEG 5000 Analyzers in Extracorporeal Membrane Oxygenation.

Abhimanyu Chandel1, Mehul Desai2, Christopher S King3, Saloni Patolia4, Anika I Raja5, Ramesh Singh6, Heidi J Dalton7.   

Abstract

Thromboelastography (TEG) evaluates viscoelastic properties of blood clot formation. The TEG 5000 analyzer is commonly used but prone to errors related to vibration or operator error. The TEG 6s was developed to overcome these limitations. Performance of TEG 6s compared with TEG 5000 has not been reported in extracorporeal membrane oxygenation (ECMO). We compared the agreement between devices via a single-center prospective observational study in hospitalized adult patients on ECMO. Data for both devices were collected daily for 3 days after ECMO initiation. Standard tests for method comparison were used. Thirty-four matching samples were available for analysis. Minimal bias was noted; however, the limit of agreement was wide for TEG parameters. Visually, agreement was better for values within the reference ranges of the tests. Lin's coefficients demonstrated moderate correlation for reaction time and alpha angle (0.58; 95% confidence interval [CI], 0.31-0.76 and 0.63; 95% CI, 0.40-0.78, respectively). Excellent correlation was demonstrated for kinetic time and maximum amplitude (0.88; 95% CI, 0.79-0.94 and 0.89; 95% CI, 0.79-0.94). The TEG 6s device may represent an acceptable surrogate for the TEG 5000 in patients on ECMO. However, limitations in reliability were noted, and the devices may not be interchangeable when results fall outside of the reference values.
Copyright © ASAIO 2021.

Entities:  

Mesh:

Year:  2022        PMID: 34852411     DOI: 10.1097/MAT.0000000000001398

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  1 in total

1.  Operability of a Resonance-Based Viscoelastic Haemostatic Analyzer in the High-Vibration Environment of Air Medical Transport.

Authors:  Johannes Zipperle; Bernhard Ziegler; Herbert Schöchl; Wolfgang Voelckel; Christoph J Schlimp; Daniel Oberladstätter
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.